Q3 2018 13F Holders as of 9/30/2018
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
28M
-
Number of holders
-
74
-
Total 13F shares, excl. options
-
20.6M
-
Shares change
-
+189K
-
Total reported value, excl. options
-
$246M
-
Value change
-
+$2.47M
-
Put/Call ratio
-
1
-
Number of buys
-
33
-
Number of sells
-
-30
-
Price
-
$11.91
Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q3 2018
84 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value as of Q3 2018.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) has 74 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20.6M shares
of 28M outstanding shares and own 73.66% of the company stock.
Largest 10 shareholders include FMR LLC (5.05M shares), Flagship Pioneering Inc. (3.2M shares), ARK Investment Management LLC (2.22M shares), Redmile Group, LLC (1.66M shares), BlackRock Inc. (1.61M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (1.27M shares), Vanguard Group Inc (1.04M shares), BAKER BROS. ADVISORS LP (575K shares), STATE STREET CORP (382K shares), and JPMORGAN CHASE & CO (370K shares).
This table shows the top 74 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.